TNGX
Tango Therapeutics, Inc.
There isn't enough reported data to score TNGX yet.
TNGX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
TNGX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
TNGX PE Valuation
TNGX has no meaningful PE right now: it lost money over the past year.
TNGX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TNGX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
TNGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | -$0.46 |
| Q2 2026 | -$0.85 | +$0.46 |
| Q1 2026 | -$0.83 | +$0.37 |
| Q4 2025 | -$0.87 | +$0.32 |
| Q3 2025 | -$0.91 | +$0.25 |
| Q2 2025 | -$1.31 | -$0.19 |
| Q1 2025 | -$1.20 | -$0.09 |
| Q4 2024 | -$1.19 | -$0.11 |
TNGX lost $1.37 per share over the past year, a bigger loss than the year before.
TNGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $53.8M | +364% |
| Q2 2025 | $3.2M | -84% |
| Q1 2025 | $5.4M | -17% |
| Q4 2024 | $4.1M | -24% |
| Q3 2024 | $11.6M | +8.2% |
| Q2 2024 | $19.9M | +36% |
| Q1 2024 | $6.5M | +12% |
| Q4 2023 | $5.4M | -15% |
TNGX's revenue has slid since its 2025 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | 26% | +309 points |
| Q2 2025 | -1288% | -1139 points |
| Q1 2025 | -789% | -136 points |
| Q4 2024 | -994% | -349 points |
| Q3 2024 | -283% | -45 points |
| Q2 2024 | -149% | +11 points |
| Q1 2024 | -653% | -128 points |
| Q4 2023 | -645% | -168 points |
TNGX's operating margin was 26% last quarter, up 309 points from the same quarter a year ago, near the top of its range since 2020.
TNGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.2M | -$6.1M |
| Q2 2026 | -$38.9M | -$1.7M |
| Q1 2026 | -$44.4M | -$2.6M |
| Q4 2025 | -$29.9M | +$6.8M |
| Q3 2025 | -$31.1M | +$2.4M |
| Q2 2025 | -$37.1M | -$13.2M |
| Q1 2025 | -$41.7M | -$3.7M |
| Q4 2024 | -$36.8M | -$9.1M |
TNGX has burned cash in almost every quarter: −$150M over the past year, against −$147M the year before.
TNGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +24.1M shares |
| 1 year | +48% | +56.1M shares |
| 3 years | +79% | +76.9M shares |
| 5 years | +3599% | +169M shares |
TNGX has 174M diluted shares, up 48% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TNGX Net Leverage
TNGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TNGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 27.6 | Neutral |
TNGX's weekly RSI is 54 (neutral) and its Stochastic is 28 (neutral).
TNGX PE vs Healthcare Sector
TNGX has no meaningful PE right now: it lost money over the past year.
TNGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.3 | 6.7% above |
| 20 week MA | $24.9 | 0% below |
| 50 week MA | $20.5 | 21% above |
| 100 week MA | $12.6 | 97% above |
| 200 week MA | $9.89 | 151% above |
TNGX's trend is mixed: it's above four of its five weekly moving averages, and 151% above its 200-week average.
TNGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $11.3 | +9.9% |
| 2021 | $11.3 | $10.9 | -2.8% |
| 2022 | $10.9 | $7.83 | -28% |
| 2023 | $7.83 | $9.90 | +26% |
| 2024 | $9.90 | $3.12 | -68% |
| 2025 | $3.12 | $8.67 | +178% |
| 2026 YTD | $8.67 | $24.9 | +187% |
TNGX's yearly returns have swung widely, from +178% in 2025 to −68% in 2024. It's up 187% so far in 2026.